Presse Med. 2012 Jun 26. [Epub ahead of print]

[Pulmonary arterial hypertension and sickle cell disease.][Article in French]

Savale L, Maitre B, Bachir D, Galactéros F, Simonneau G, Parent F.

Université Paris-Sud, faculté de médecine, 94276 Kremlin-Bicêtre, France; AP-HP, hôpital Bicêtre, centre de référence de l'hypertension pulmonaire sévère, service de pneumologie et réanimation respiratoire, 94275 Le Kremlin-Bicêtre, France; Inserm U999, hypertension artérielle pulmonaire : physiopathologie et innovation thérapeutique, 92350 Le Plessis-Robinson, France.

Abstract

Recent hemodynamic studies performed in large cohorts of adult patients with sickle cell disease have established the prevalence of pulmonary hypertension in this disease about 6 to 10%. Over half of these correspond to postcapillary pulmonary hypertension. Precapilliary arterial pulmonary hypertension seems to be a relatively infrequent complication of the disease. It is characterized by a different hemodynamic profile of idiopathic PAH with lower levels of pulmonary pressures and pulmonary vascular resistance. However, pulmonary vascular disease appears to have a significant impact on the functional status and vital prognosis of patients with sickle cell disease. The predictive value of echocardiography to detect pulmonary hypertension in this population is low (25-32%) when the threshold of tricuspid regurgitation velocity of 2.5m/s is used. At present, no specific treatments for pulmonary arterial hypertension is currently approved for the treatment of PAH associated with sickle cell disease due to lack of data in this specific population.

PMID: 22743045